Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 15Lymphoma, Follicular 10Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Sezary Syndrome 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neoplasms 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2

Interventions

tofacitinib 5apremilast 1Lidocaine 1Etanercept 1Blood Specimen Collection 1Biopsy 1Aprepitant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pruritus × Blood Specimen Collection × Lymphoid × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡